Details for Patent: 7,612,176
Summary for Patent: 7,612,176
| Title: | Polymer-based sustained release device | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Steven G. Wright, Troy Christensen, Thean Yeoh, Michael E. Rickey, Joyce M. Hotz, Rajesh Kumar, Henry R. Costantino | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Alkermes Pharma Ireland Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US11/826,535 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Composition; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 7,612,176: Claim Scope, Expiration, Exenatide Relevance, and Patent LandscapeUS Patent 7,612,176 covers a narrow sustained-release peptide composition based on a biodegradable polymer, a glucoregulatory peptide at approximately 3% to 5% by weight, and a sugar at approximately 2% by weight. The strongest claim position is directed to a formulation containing approximately 5% peptide, approximately 2% sucrose, and a 1:1 poly(lactide-co-glycolide), or PLGA, polymer. The patent is relevant to long-acting exenatide products because exendin-3 and exendin-4 are expressly included in the claims. Its commercial significance is limited by the patent’s expiration, the narrow concentration requirements, and the existence of later patents directed to specific exenatide microspheres, manufacturing processes, dosing regimens, and commercial product formulations. What does US Patent 7,612,176 claim?The patent has two independent claim categories:
Claim 1 is the broadest composition claim. It requires every element below:
Claim 16 is the corresponding independent treatment claim. It requires administration of the formulation to a patient with Type 2 diabetes in a therapeutically effective amount. The patent does not require a particular particle size, injection volume, release duration, pharmacokinetic profile, or manufacturing process in the independent composition claim. Those omissions broaden the technical formulation concept but leave the claim dependent on precise compositional limitations. How does the “consisting essentially of” language limit infringement?The phrase “consisting essentially of” creates a partially closed claim. A formulation can contain ingredients not expressly recited, but an additional ingredient may defeat infringement if it materially alters the release rate of the polypeptide. This limitation has two consequences. First, ordinary excipients may be permissible if they do not materially change peptide release. Buffers, stabilizers, tonicity agents, or processing residues would require a fact-specific analysis. Second, a formulation containing a deliberate release modifier may fall outside the claim even if it uses the same PLGA polymer, peptide, and sugar concentrations. Examples could include:
The claim does not exclude all additional ingredients. It excludes additional ingredients that alter the peptide release rate. That creates a technical and legal dispute over the baseline release profile, the magnitude of the change, and whether the ingredient was included for a release-control function. What polymers are covered by US 7,612,176?Dependent claim 2 covers a broad Markush group:
Claim 3 narrows the polymer to PLGA with an approximately 1:1 lactide-to-glycolide ratio. This limitation is important because PLGA composition affects polymer degradation, water uptake, erosion, and peptide release. Polymer claim hierarchy
The use of “about” gives the patentee flexibility around the stated 1:1 ratio. It does not necessarily cover every commercial PLGA grade. A formulation using a materially different lactide:glycolide ratio would have a stronger noninfringement position under the literal wording, although equivalence issues could remain. What peptides and sugars are protected?The claims cover a broad class of polypeptides, with a narrower glucoregulatory peptide subgroup. Peptide scopeClaim 10 covers glucoregulatory peptides and pharmaceutically acceptable salts. Claim 11 identifies:
Claim 12 narrows the list to:
Claim 15 further narrows the peptide to exendin-3 and exendin-4. The claims therefore reach beyond exenatide. Exenatide is a synthetic version of exendin-4, making exendin-4 the most commercially relevant species for the patent’s claim set. Sugar scopeClaim 6 covers:
Claim 7 specifies sucrose, mannitol, or both. Claim 8 limits the sugar to sucrose. Claims 9 and 14 combine sucrose with peptide-specific limitations. The commercially most significant combination is:
That combination is most directly captured by claims 13, 14, and 15, read together with the independent composition claim. Which claims are strongest for an exenatide product?The most commercially relevant claims are claims 9, 13, 14, and 15.
Claims 20 and 21 are particularly specific. A product would need to satisfy the composition limitations and the treatment-use limitations. Claim 21 requires injection, which is commercially relevant for depot exenatide products but limits the claim compared with the composition claims. What does the patent exclude from the claim scope?The claims do not expressly require:
A competitor could seek design-around protection by changing one or more required elements. Potential design-around approaches include:
These approaches require technical validation. The “about” ranges and the doctrine of equivalents can reduce the certainty of a concentration-based design-around. When did US Patent 7,612,176 expire?US Patent 7,612,176 was issued on November 3, 2009. Public patent records identify a priority date in December 2003 and a nominal patent-term endpoint in December 2024, subject to any applicable patent-term adjustment or other statutory modification.[1] On that basis, the patent is no longer an enforceable US patent after expiration of its statutory term. Patent expiration does not eliminate its historical relevance to products launched during the enforceable period, nor does it eliminate the value of related continuation, divisional, or improvement patents with later expiration dates. The patent should therefore be analyzed in two periods:
The precise enforceability history should be confirmed against the USPTO maintenance-fee and patent-term records before use in litigation, licensing, or freedom-to-operate analysis.[1] Was US 7,612,176 an Orange Book patent?The patent’s relevance to an FDA-approved exenatide product does not establish that it was listed in the FDA Orange Book. Orange Book listing is product-specific and depends on whether the patent claims the approved drug substance, formulation, composition, or method of use under FDA listing standards.[2] For an exenatide extended-release product, the relevant Orange Book analysis should distinguish:
A broad peptide-depot patent may be relevant to the product yet not appear in the Orange Book if it does not meet listing requirements or was not submitted for listing. Conversely, later patents may provide the principal regulatory barrier even after an earlier platform patent expires. What FDA products are relevant to the patent?The principal commercial product associated with the claimed technology is extended-release exenatide, marketed in the United States as Bydureon and later Bydureon BCise. Bydureon was approved under NDA 022200, and Bydureon BCise was approved under a separate NDA.[3][4] The regulatory formulation uses biodegradable microsphere technology to deliver exenatide over an extended period. The FDA labeling describes exenatide extended-release as a once-weekly injectable product and identifies the relevant administration and reconstitution requirements.[3][4] The patent claims are broader than the commercial product in some respects because they cover multiple glucoregulatory peptides and polymer systems. They are narrower in others because of the approximately 3% to 5% peptide concentration, approximately 2% sugar concentration, and exclusion of ingredients that alter release. What later patents are likely to matter more than US 7,612,176?The later patent landscape for extended-release exenatide generally falls into five groups. Exenatide microsphere formulation patentsThese patents tend to claim specific microsphere characteristics, polymer molecular weight, particle morphology, encapsulation efficiency, peptide loading, and release profiles. They may provide stronger product-specific coverage than the earlier platform claims. Manufacturing-process patentsManufacturing patents can cover:
These patents may create a practical manufacturing barrier even where the composition patent has expired. Reconstitution and delivery patentsCommercial extended-release exenatide products require product-specific mixing and injection steps. Later patents may cover:
Such patents can remain relevant after the basic PLGA composition patent expires. Method-of-use patentsLater patents may claim:
US 7,612,176 contains method claims for treating Type 2 diabetes, but it does not expressly require once-weekly dosing. Later dosing patents may therefore provide separate exclusivity. Polymer and peptide manufacturing patentsPatents directed to peptide purity, synthetic intermediates, aggregation control, peptide stabilization, and polymer quality can affect generic or follow-on development even if they do not claim the final dosage form. Does US 7,612,176 create biosimilar risk?The principal regulatory pathway for a follow-on exenatide product would generally be an abbreviated new drug application, or ANDA, rather than the 351(k) biosimilar pathway used for biological products regulated under the Public Health Service Act. Exenatide is a peptide drug. A follow-on sponsor would need to assess whether the reference product and proposed product qualify for the relevant small-molecule or peptide drug pathway, whether the formulation is pharmaceutically equivalent, and whether the FDA requires additional clinical or comparative evidence. The patent itself does not create a biosimilar-specific barrier. The relevant risks are:
Which companies could challenge the patent or related patents?Potential challengers would include generic injectable manufacturers, specialty peptide companies, and contract manufacturers developing PLGA depot products. The relevant challenge mechanisms would have included:
For US 7,612,176 specifically, the patent’s expiration materially reduces the value of a new validity challenge. The commercial contest is more likely to center on later patents covering the approved product, its manufacturing method, delivery device, or dosing regimen. No reliable conclusion about a specific Paragraph IV challenge or settlement should be drawn from the claim text alone. Those issues require the patent’s litigation docket, FDA Orange Book history, and relevant ANDA records. How strong is the patent estate?US 7,612,176 was a meaningful platform patent during its term but is not, by itself, a complete modern exclusivity position for an extended-release exenatide product.
The patent’s strongest historical position was against a formulation matching the claimed composition without a release-modifying excipient. Its weakest points were the narrow concentration windows, the absence of manufacturing claims, and the lack of a required release-duration or particle-specific limitation. What generic launch scenarios exist after expiration?After expiration of US 7,612,176, three launch scenarios are relevant. Scenario 1: Direct formulation replicationA competitor could seek to reproduce the peptide, PLGA, sugar, and microsphere architecture while clearing later patents. The primary risks would shift to later product-specific patents, regulatory equivalence, and manufacturing know-how. Scenario 2: Formulation design-aroundA competitor could use a different polymer ratio, peptide loading, sugar system, or release-control mechanism. This may reduce exposure to the historical claim set but increase FDA comparability and development risk. Scenario 3: Alternative long-acting GLP-1 productA sponsor could avoid the PLGA depot platform entirely by developing a chemically modified GLP-1 receptor agonist, a different injectable depot, an implant, or another extended-release technology. Competing products such as dulaglutide, semaglutide, liraglutide, and tirzepatide operate under different active-ingredient and formulation patent estates. How does US 7,612,176 compare with competing GLP-1 patent estates?
US 7,612,176 is best characterized as an expired platform-level formulation patent, not as the complete exclusivity foundation for the modern GLP-1 market. Key Takeaways
FAQsDoes US 7,612,176 cover all exenatide products?No. It covers only products satisfying the specified polymer, peptide concentration, sugar concentration, dispersion, and release-modifier limitations. Immediate-release exenatide and formulations using materially different compositions may fall outside the claims. Does the patent require a 1:1 PLGA ratio?No. Claim 1 does not require PLGA or a 1:1 ratio. Those limitations appear in dependent claims, including claims 3, 13, 17, and 20. Could a formulation with mannitol infringe instead of sucrose?Potentially. Claims 6 and 7 expressly cover mannitol, while claim 8 and certain combination claims are limited to sucrose. The answer depends on which claim is asserted and whether the formulation satisfies the approximately 2% sugar requirement. Is a formulation with a release modifier outside the patent?It may be outside the literal claims if the added ingredient alters the peptide release rate. That conclusion depends on the ingredient’s technical function and the resulting release profile. Does patent expiration eliminate all barriers to a generic extended-release exenatide launch?No. Expiration of US 7,612,176 removes that patent as a prospective blocking right, but later formulation, process, device, method-of-use, and Orange Book-listed patents may continue to affect launch timing. References
More… ↓ |
Drugs Protected by US Patent 7,612,176
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 7,612,176
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2005235100 | ⤷ Start Trial | |||
| Brazil | PI0509946 | ⤷ Start Trial | |||
| Canada | 2560874 | ⤷ Start Trial | |||
| Canada | 2798552 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
